Attenuated bacteria as effectors in cancer immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Microbial Therapy

Background:

• Cancer remains a leading cause of death, characterized by low antigenicity and high tumorigenicity.
• Novel therapies aim to boost tumor antigenicity and immune cell function.
• Attenuated bacteria, like Salmonella typhimurium, show promise as oncolytic agents due to tumor-homing properties.

Purpose of the Study:

• To investigate the efficacy of genetically engineered Salmonella typhimurium expressing cytokines as a cancer therapy.
• To evaluate the potential of a cytokine-encoding Salmonella strain in retarding experimental melanoma growth.

Main Methods:

• Utilized attenuated strains of Salmonella typhimurium, genetically modified to express murine cytokines.
• Treated mice with melanoma cells using an attenuated S. typhimurium strain or a derivative expressing interleukin-2 (IL-2).

Main Results:

• IL-2-encoding Salmonella organisms demonstrated superior suppression of tumor growth compared to the parental strain.
• Data support the potential of cytokine-expressing attenuated Salmonella in cancer treatment.

Conclusions:

• Genetically engineered, cytokine-expressing Salmonella typhimurium can effectively inhibit tumor growth.
• This approach represents a promising strategy for enhancing cancer therapy by modulating the immune response within the tumor microenvironment.